These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 23622408)

  • 21. [Principles of therapeutic approaches for mucopolysaccharidoses].
    Caillaud C
    Arch Pediatr; 2014 Jun; 21 Suppl 1():S39-45. PubMed ID: 25063383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of brain disease in the mucopolysaccharidoses.
    Scarpa M; Orchard PJ; Schulz A; Dickson PI; Haskins ME; Escolar ML; Giugliani R
    Mol Genet Metab; 2017 Dec; 122S():25-34. PubMed ID: 29153844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the central nervous system in lysosomal storage diseases: Strategies to deliver therapeutics across the blood-brain barrier.
    Critchley BJ; Gaspar HB; Benedetti S
    Mol Ther; 2023 Mar; 31(3):657-675. PubMed ID: 36457248
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stop-codon read-through for patients affected by a lysosomal storage disorder.
    Brooks DA; Muller VJ; Hopwood JJ
    Trends Mol Med; 2006 Aug; 12(8):367-73. PubMed ID: 16798086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene expression-targeted isoflavone therapy.
    Węgrzyn A
    IUBMB Life; 2012 Apr; 64(4):307-15. PubMed ID: 22362546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Orphan drug development.
    Pastores GM; Gupta P
    Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():64-7. PubMed ID: 24380124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiac involvement in Lysosomal Storage Diseases.
    Sestito S; Parisi F; Tallarico V; Tarsitano F; Roppa K; Pensabene L; Chimenz R; Ceravolo G; Calabrò MP; De Sarro R; Moricca MT; Bonapace G; Concolino D
    J Biol Regul Homeost Agents; 2020; 34(4 Suppl. 2):107-119. SPECIAL ISSUE: FOCUS ON PEDIATRIC CARDIOLOGY. PubMed ID: 33000609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene therapy for the lysosomal storage disorders.
    Cabrera-Salazar MA; Novelli E; Barranger JA
    Curr Opin Mol Ther; 2002 Aug; 4(4):349-58. PubMed ID: 12222873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enzyme reconstitution/replacement therapy for lysosomal storage diseases.
    Burrow TA; Hopkin RJ; Leslie ND; Tinkle BT; Grabowski GA
    Curr Opin Pediatr; 2007 Dec; 19(6):628-35. PubMed ID: 18025928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Musculoskeletal manifestations in lysosomal storage diseases].
    Kovac I
    Reumatizam; 2011; 58(2):182-4. PubMed ID: 22232961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatments for lysosomal storage disorders.
    Lachmann R
    Biochem Soc Trans; 2010 Dec; 38(6):1465-8. PubMed ID: 21118108
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease.
    Suzuki Y
    Brain Dev; 2013 Jun; 35(6):515-23. PubMed ID: 23290321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Newborn screening for lysosomal storage disorders.
    Meikle PJ; Grasby DJ; Dean CJ; Lang DL; Bockmann M; Whittle AM; Fietz MJ; Simonsen H; Fuller M; Brooks DA; Hopwood JJ
    Mol Genet Metab; 2006 Aug; 88(4):307-14. PubMed ID: 16600651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enzyme enhancement therapeutics for lysosomal storage diseases: Current status and perspective.
    Thomas R; Kermode AR
    Mol Genet Metab; 2019 Feb; 126(2):83-97. PubMed ID: 30528228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stem Cell Applications in Lysosomal Storage Disorders: Progress and Ongoing Challenges.
    Köse S; Aerts-Kaya F; Uçkan Çetinkaya D; Korkusuz P
    Adv Exp Med Biol; 2021; 1347():135-162. PubMed ID: 33977438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oxidative damage and redox in Lysosomal Storage Disorders: Biochemical markers.
    Donida B; Jacques CED; Mescka CP; Rodrigues DGB; Marchetti DP; Ribas G; Giugliani R; Vargas CR
    Clin Chim Acta; 2017 Mar; 466():46-53. PubMed ID: 28082023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological chaperones for enzyme enhancement therapy in genetic diseases.
    Aymami J; Barril X; Rodríguez-Pascau L; Martinell M
    Pharm Pat Anal; 2013 Jan; 2(1):109-24. PubMed ID: 24236974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of antibodies in enzyme treatments and therapeutic strategies.
    Bigger BW; Saif M; Linthorst GE
    Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):183-94. PubMed ID: 25987172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic approaches for lysosomal storage diseases: a patent update.
    Urbanelli L; Sagini K; Polidoro M; Brozzi A; Magini A; Emiliani C
    Recent Pat CNS Drug Discov; 2013 Aug; 8(2):91-109. PubMed ID: 23713988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-neuronopathic lysosomal storage disorders: Disease spectrum and treatments.
    Pastores GM; Hughes DA
    Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):173-82. PubMed ID: 25987171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.